Abivax S.A. (ABVX) Financial Ratios
12 years of historical data (2014–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
13.33
+16% vs avg
5yr avg: 11.44
30Y Low2.4·High20.6
ROE
↑
-135.6%
↓+32% vs avg
5yr avg: -198.1%
30Y Low-367%·High-15%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ABVX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Abivax S.A. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6.6B | $9.4B | $461M | $461M | — | — | — | — | — | — | — |
| Enterprise Value | $6.1B | $8.9B | $415M | $267M | — | — | — | — | — | — | — |
| P/E Ratio → | -18.76 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 13.33 | 20.61 | 11.37 | 2.35 | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ABVX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
ABVX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -135.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | -53623.8% | -1409300.0% | -85327.8% | -144970.0% | -11431.5% |
| Operating Margin | — | — | — | — | — | — | -60330.2% | -1664800.0% | -106155.6% | -141500.0% | -14359.1% |
| Net Profit Margin | — | — | — | — | — | — | -59604.8% | -1531700.0% | -87905.6% | -112230.0% | -11266.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -135.6% | -135.6% | -149.0% | -145.4% | -366.8% | -193.7% | -205.8% | -115.1% | -38.2% | -21.4% | -22.3% |
| ROA | -85.2% | -85.2% | -66.2% | -73.4% | -65.7% | -47.0% | -61.0% | -57.9% | -29.3% | -19.6% | -20.9% |
| ROIC | — | — | — | -888.2% | -268.0% | -157.3% | -109.3% | -74.4% | -34.2% | -22.2% | -28.5% |
| ROCE | -77.7% | -77.7% | -98.5% | -96.9% | -128.3% | -64.3% | -83.3% | -78.4% | -40.7% | -26.8% | -28.1% |
ABVX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $516M exceeds total debt of $32M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 2.40 | 0.30 | 5.45 | 1.99 | 1.90 | 1.12 | 0.31 | — | 0.01 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.06 | -1.15 | -0.99 | 1.70 | -0.35 | 0.26 | 0.59 | 0.08 | -0.04 | -0.13 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -10.60 | -10.60 | -13.18 | -9.69 | -7.75 | -10.93 | -18.46 | -21.00 | -41.21 | — | -427.05 |
Net cash position: cash ($516M) exceeds total debt ($32M)
ABVX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Abivax S.A.'s current ratio of 8.75x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.25x to 8.75x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.75 | 8.75 | 1.84 | 3.25 | 0.70 | 2.33 | 1.94 | 1.47 | 2.47 | 3.84 | 7.85 |
| Quick Ratio | 8.75 | 8.75 | 1.84 | 3.25 | 0.70 | 2.21 | 1.94 | 1.38 | 2.47 | 3.80 | 7.83 |
| Cash Ratio | 8.42 | 8.42 | 1.55 | 2.96 | 0.52 | 1.88 | 1.51 | 0.79 | 1.53 | 3.13 | 6.48 |
| Asset Turnover | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | — | — | — | — | — | 11.38 | — | 24.47 | — | 72.90 | 281.63 |
| Days Sales Outstanding | — | — | — | — | — | — | 46580.95 | 999999.00 | 157619.17 | 133115.50 | 13803.90 |
ABVX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Abivax S.A. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Shares Outstanding | — | $70M | $63M | $43M | $19M | $15M | $14M | $12M | $10M | $10M | $10M |
Peer Comparison
Compare ABVX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ABVXYou | $7B | -18.8 | — | — | — | — | -135.6% | — | — |
 ARRY | $1B | -10.2 | 12.7 | 14.4 | 21.2% | 6.6% | -19.0% | 9.0% | 5.8 |
 PTGX | $7B | -53.6 | — | 125.9 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 PRTA | $432M | -1.8 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 ARDX | $1B | -22.3 | — | — | 89.5% | -10.1% | -36.2% | -10.7% | — |
 RCKT | $290M | -1.3 | — | — | — | — | -60.3% | -62.4% | — |
 ABBV | $398B | 94.8 | 16.3 | 22.3 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 JNJ | $574B | 41.2 | 19.9 | 28.9 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
 LLY | $1.1T | 50.6 | 36.2 | 122.3 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 GILD | $156B | 18.6 | 12.0 | 16.5 | 78.8% | 39.7% | 40.7% | 23.2% | 1.7 |
 REGN | $64B | 14.7 | 15.3 | 15.6 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
What if you invested $1,000 in ABVX 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in ABVX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs ABVX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationABVX vs ARRY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Array Technologies, Inc..
Compare NowABVX — Frequently Asked Questions
Quick answers to the most common questions about buying ABVX stock.
What is Abivax S.A.'s P/E ratio?
Abivax S.A.'s current P/E ratio is -18.8x. This places it at the 50th percentile of its historical range.
What is Abivax S.A.'s ROE?
Abivax S.A.'s return on equity (ROE) is -135.6%. The historical average is -119.9%.
Is ABVX stock overvalued?
Based on historical data, Abivax S.A. is trading at a P/E of -18.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.